Cost-of-illness study in acromegalic patients in Italy

G. Didoni, S. Grottoli, V. Gasco, M. Battistini, D. Ferone, M. Giusti, F. Ragazzoni, P. Ruffo, E. Ghigo, F. Minuto

Research output: Contribution to journalArticlepeer-review


Introduction: acromegalic therapeutic goals are directed at removing the tumor, preventing tumor re-growth and reducing longterm morbidity and mortality. In this scenario, the acromegalic patient needs a variety of health resources (diagnostic tests, surgery, radiotherapy, specialist visits and drugs) for his/her cure, in order to decrease/stop the progression of the disease and to cure the co-morbid diseases. Lack of epidemiological data has suggested performing an Italian retrospective study aiming to assess the health resource consumption that is caused by acromegalic cure and the relative co-morbidities, in order to estimate the amount of the direct costs of acromegalic patients. Method: a retrospective study was performed on a total of 134 patients (142 patients selected, 76 in Genoa and 66 in Turin) for aperiod of about 7 yr preceding the enrolment date. Only direct costs were evaluated by performing an analysis on the perspective of Italian Healthcare Service (SSN). Results: the mean total direct costs for acromegaly cure ranged from 7.968,41 to 12.533,02 €/yr (p

Original languageEnglish
Pages (from-to)1034-1039
Number of pages6
JournalJournal of Endocrinological Investigation
Issue number11
Publication statusPublished - Dec 2004


  • Acromegaly
  • Cost
  • Health resource

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Cost-of-illness study in acromegalic patients in Italy'. Together they form a unique fingerprint.

Cite this